Natera EBITDA 2014-2024 | NTRA
Natera annual and quarterly EBITDA history from 2014 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Natera EBITDA for the quarter ending December 31, 2024 was $-0.057B, a 27.14% decline year-over-year.
- Natera EBITDA for the twelve months ending December 31, 2024 was $-0.191B, a 54.51% decline year-over-year.
- Natera 2024 annual EBITDA was $-0.191B, a 54.51% decline from 2023.
- Natera 2023 annual EBITDA was $-0.42B, a 19% decline from 2022.
- Natera 2022 annual EBITDA was $-0.518B, a 15.71% increase from 2021.
| Natera Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $-191 |
| 2023 | $-420 |
| 2022 | $-518 |
| 2021 | $-448 |
| 2020 | $-202 |
| 2019 | $-107 |
| 2018 | $-106 |
| 2017 | $-127 |
| 2016 | $-93 |
| 2015 | $-54 |
| 2014 | $6 |
| 2013 | $-23 |
| Natera Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-57 |
| 2024-09-30 | $-31 |
| 2024-06-30 | $-36 |
| 2024-03-31 | $-67 |
| 2023-12-31 | $-78 |
| 2023-09-30 | $-103 |
| 2023-06-30 | $-106 |
| 2023-03-31 | $-132 |
| 2022-12-31 | $-137 |
| 2022-09-30 | $-113 |
| 2022-06-30 | $-137 |
| 2022-03-31 | $-132 |
| 2021-12-31 | $-134 |
| 2021-09-30 | $-145 |
| 2021-06-30 | $-111 |
| 2021-03-31 | $-58 |
| 2020-12-31 | $-69 |
| 2020-09-30 | $-54 |
| 2020-06-30 | $-46 |
| 2020-03-31 | $-32 |
| 2019-12-31 | $-32 |
| 2019-09-30 | $-19 |
| 2019-06-30 | $-26 |
| 2019-03-31 | $-30 |
| 2018-12-31 | $-28 |
| 2018-09-30 | $-25 |
| 2018-06-30 | $-25 |
| 2018-03-31 | $-28 |
| 2017-12-31 | $-45 |
| 2017-09-30 | $-24 |
| 2017-06-30 | $-26 |
| 2017-03-31 | $-33 |
| 2016-12-31 | $-40 |
| 2016-09-30 | $-25 |
| 2016-06-30 | $-21 |
| 2016-03-31 | $-8 |
| 2015-12-31 | $-16 |
| 2015-09-30 | $-19 |
| 2015-06-30 | $-14 |
| 2015-03-31 | $-5 |
| 2014-12-31 | |
| 2014-09-30 | $6 |
| 2014-06-30 | $-1 |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $19.117B | $1.697B |
| Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.516B | 27.37 |
| Elevance Health (ELV) | United States | $98.469B | 13.19 |
| CVS Health (CVS) | United States | $85.419B | 12.50 |
| Cencora (COR) | United States | $53.926B | 19.57 |
| DiDi Global (DIDIY) | China | $23.525B | 0.00 |
| BioMerieux (BMXMF) | France | $14.914B | 0.00 |
| ICON (ICLR) | Ireland | $14.132B | 12.84 |
| Solventum (SOLV) | United States | $13.154B | 12.27 |
| Revvity (RVTY) | United States | $12.712B | 21.59 |
| Avantor (AVTR) | United States | $11.045B | 16.21 |
| CochLear (CHEOY) | Australia | $10.877B | 0.00 |
| Doximity (DOCS) | United States | $10.834B | 56.34 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.609B | 0.00 |
| Viatris (VTRS) | United States | $10.397B | 3.29 |
| Medpace Holdings (MEDP) | United States | $9.283B | 24.12 |
| Sonic Healthcare (SKHHY) | Australia | $7.768B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.697B | 14.59 |
| HealthEquity (HQY) | United States | $7.644B | 37.60 |
| Bausch + Lomb (BLCO) | Canada | $5.111B | 23.39 |
| Amplifon S.p.A (AMFPF) | Italy | $4.961B | 26.19 |
| Organon (OGN) | United States | $3.841B | 3.91 |
| Alignment Healthcare (ALHC) | United States | $3.572B | 0.00 |
| Sotera Health (SHC) | United States | $3.305B | 19.11 |
| BrightSpring Health Services (BTSG) | United States | $3.165B | 32.89 |
| Surgery Partners (SGRY) | United States | $3.031B | 34.93 |
| Concentras Parent (CON) | United States | $2.781B | 14.47 |
| GeneDx Holdings (WGS) | United States | $2.486B | 295.22 |
| Ardent Health Partners (ARDT) | United States | $1.963B | 0.00 |
| Progyny (PGNY) | United States | $1.908B | 42.15 |
| Agilon Health (AGL) | United States | $1.785B | 0.00 |
| Premier (PINC) | United States | $1.760B | 11.27 |
| PACS (PACS) | United States | $1.713B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.692B | 36.75 |
| Teladoc Health (TDOC) | United States | $1.382B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.243B | 10.42 |
| Establishment Labs Holdings (ESTA) | $1.177B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $1.031B | 0.00 |
| CareDx (CDNA) | United States | $0.984B | 16.75 |
| AMN Healthcare Services Inc (AMN) | United States | $0.934B | 7.39 |
| Embecta (EMBC) | United States | $0.741B | 5.08 |
| QDM (QDMI) | Hong Kong, SAR China | $0.526B | 13.77 |
| Auna S.A (AUNA) | Luxembourg | $0.526B | 13.94 |
| Enhabit (EHAB) | United States | $0.444B | 41.86 |
| Sonida Senior Living (SNDA) | United States | $0.441B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.403B | 0.00 |
| SBC Medicals (SBC) | United States | $0.329B | 0.00 |
| DocGo (DCGO) | United States | $0.269B | 11.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.265B | 0.00 |
| Nutex Health (NUTX) | United States | $0.256B | 5.10 |
| LifeMD (LFMD) | United States | $0.243B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.232B | 0.00 |
| Beauty Health (SKIN) | United States | $0.168B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.139B | 0.00 |
| So-Young (SY) | China | $0.098B | 0.00 |
| Biodesix (BDSX) | United States | $0.091B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.090B | 0.00 |
| OncoCyte (OCX) | United States | $0.088B | 0.00 |
| Oncology Institute (TOI) | United States | $0.086B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.075B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.065B | 0.00 |
| NeueHealth (NEUE) | United States | $0.056B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.026B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.024B | 0.00 |
| ModivCare (MODV) | United States | $0.019B | 6.57 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| KindlyMD (KDLY) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.001B | 0.00 |
| Aclarion (ACON) | United States | $0.000B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |